Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07238816 · ClinicalTrials.gov registry record · Phase 1

A Research Study Looking at How Food Intake Affects Inno8 in the Body of Healthy People

A Phase 1 study of Haemophilia A, sponsored by Novo Nordisk A/S.

Recruiting
Registry status
Phase 1
Development phase
80
Enrollment target
1
Study location

NCT07238816: Recruiting Phase 1 study of Haemophilia A, sponsored by Novo Nordisk A/S.

NCT07238816 is a Phase 1 study of Haemophilia A that is actively recruiting participants, run by Novo Nordisk A/S. The registered enrollment target is 80 participants, below the 215-participant average among 8 other Haemophilia A trials with a reported enrollment target (63% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07238816, a Phase 1 study of Haemophilia A, is actively recruiting participants, sponsored by Novo Nordisk A/S.

RECRUITING
Registry status
Phase 1
Development phase
80 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to test a new medicine called Inno8. The study will test how eating and drinking before and after taking Inno8 affects how well it is absorbed in the stomach. The study consists of four arms. Participants will take the study medicine after an overnight fast. How long participants will need to fast depends on which group participants are in. After taking the study medicine, participants will need to fast again. The study will last for up to 9.5 weeks.

Primary Outcome

Measured as nanograms\*day per millilitre (ng\*day/mL).

Conditions Studied

Interventions

  • DRUG NNC0442-0344 A

Study Locations (1)

California

  • Altasciences Clinical LA, Inc. - Cypress

Trial Details

FieldValue
Enrollment Target 80 participants
Start Date 2025-11-18
Est. Completion 2026-04-29
Phase Phase 1
Novo Nordisk A/S

431 total trials

What NCT07238816 shows while recruiting

NCT07238816 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 80 participants, a relatively small participant target, below the 215-participant average among 8 other Haemophilia A trials with a reported enrollment target (63% lower).

The record links to 1 condition, with Haemophilia A appearing as the primary indexed condition, and to 1 intervention - of which NNC0442-0344 A is the first listed.

NCT07238816 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT07238816 about?

NCT07238816 is a clinical study titled "A Research Study Looking at How Food Intake Affects Inno8 in the Body of Healthy People". The purpose of this study is to test a new medicine called Inno8. The study will test how eating and drinking before and after taking Inno8 affects how well it is absorbed in the stomach. The study consists of four arms. Participants will take the study medicine after an overnight fast. How long par...

What is the current status of trial NCT07238816?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 80 participants. The study started on 2025-11-18. Estimated completion is 2026-04-29.

What conditions does trial NCT07238816 study?

This clinical trial studies the following conditions: Haemophilia A.

What interventions are being tested in trial NCT07238816?

The interventions under investigation include: NNC0442-0344 A (DRUG).

Who is sponsoring clinical trial NCT07238816?

This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07238816 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Haemophilia A

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT07238816's enrollment target sits among peer trials

80 6th of 8 higher than 3 of 8 other Haemophilia A trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Haemophilia A trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01243931 · 80 participants · NA

    Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy

  • NCT01659203 · 80 participants · Phase 1

    Proton or Photon RT for Retroperitoneal Sarcomas

  • NCT01803451 · 80 participants · Early Phase 1

    Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass

  • NCT01964859 · 80 participants · Phase 2

    Feasibility Study for Fibroblast Autologous Skin Grafts

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT07238816, the US trial registry maintained by the National Library of Medicine. NCT07238816 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.